|
Synonyms: RSLV132
Compound class:
Peptide or derivative
Comment: RSLV-132 is a fully human biologic fusion protein that is comprised of human RNase fused to the Fc domain of human IgG1 [1]. The peptide sequence of RSLV-132 has not yet been formally disclosed.
|
| No information available. |
Summary of Clinical Use  |
| RSLV-132 has been advanced to clinical evaluations in autoinflammatory conditions. It has been entered into a clinical study to determine efficacy in patients with long-COVID. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02660944 | A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) | Phase 2 Interventional | Resolve Therapeutics | ||
| NCT04944121 | Phase 2 Study of RSLV-132 in Subjects With Long COVID | Phase 2 Interventional | Resolve Therapeutics | ||
| NCT02194400 | Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus | Phase 1 Interventional | Resolve Therapeutics | 1 | |
| NCT03247686 | A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome | Phase 2 Interventional | Resolve Therapeutics | 4 | |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
